ArticleBiochemistry and biophysics reports2026
Identification of potential biomarkers and therapeutic targets for liver cirrhosis based on Mendelian randomization and machine learning.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Liver cirrhosis(LC) represents the end stage of chronic liver disease, yet reliable molecular markers remain limited. This study aimed to uncover potential diagnostic biomarkers and therapeutic targets for LC. Methods: We integrated differential gene analysis from LC datasets in the Gene Expression Omnibus (GEO) with Mendelian randomization (MR) using eQTLGen and FinnGen summary data to prioritize LC-associated genes. LASSO, SVM-RFE, RF, and XGBoost algorithms were applied to refine candidate genes. Based on these, we constructed a nomogram risk prediction model and evaluated by receiver operating characteristic (ROC) curve. Gene set enrichment analysis (GSEA) and immune infiltration profiling were conducted to explore potential biological functions. Additionally, potential therapeutic compounds targeting these genes were screened using Drug Signatures Database (DSigDB) via Enrichr platform. Finally, hub genes were validated by immunohistochemistry (IHC). Results: Through integrative analysis,we identified five hub genes: ENPP2, FAM134B, PPARGC1A, SLFN11, and TRIM22. A nomogram based on these genes demonstrated strong predictive performance (AUC = 0.944 in the training set; AUC = 0.909 in the validation set). GSEA linked these genes to antigen processing, cell adhesion, and immune regulation. Immune infiltration analysis indicated that abnormal levels of resting NK cells (P < 0.001), M2 macrophages (P = 0.002), activated dendritic cells (P < 0.001), and neutrophils (P = 0.038) in LC. Drug prediction provides promising treatment options for LC, including valproic acid and tamoxifen. Conclusion: Our integrated approach identified five hub genes associated with LC, providing valuable clues to predict and treat LC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.